Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
Noosa News21 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
General8 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Business21 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News23 hours agoNSW farmer calls for hunting buffer zones after bullets hit property